PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

Purpose: In human leukocyte antigen (HLA)–matched stem cell transplantation (SCT), it has been shown that beneficial immune response mediating graft-versus-tumor (GVT) responses can be separated from graft-versus-host disease (GVHD) immune responses. In this study, we investigated whether it would be possible to dissect the beneficial immune response of allo-HLA–reactive T cells with potent antitumor reactivity from GVHD-inducing T cells present in the detrimental immune response after HLA-mismatched SCT. Experimental Design: The presence of specific tumor-reactive T cells in the allo-HLA repertoire was analyzed at the time of severe GVHD after HLA-mismatched SCT, using tetramers composed of different tumor-associated antigens (TAA). Results: High-avidity allo-HLA-restricted T cells specific for the TAA preferentially expressed antigen on melanomas (PRAME) were identified that exerted highly single-peptide–specific reactivity. The T cells recognized multiple different tumor cell lines and leukemic cells, whereas no reactivity against a large panel of nonmalignant cells was observed. These T cells, however, also exerted low reactivity against mature dendritic cells (DC) and kidney epithelial cells, which was shown to be because of low PRAME expression. Conclusions: On the basis of potential beneficial specificity and high reactivity, the T-cell receptors of these PRAME-specific T cells may be effective tools for adoptive T-cell therapy. Clinical studies have to determine the significance of the reactivity observed against mature DCs and kidney epithelial cells. Clin Cancer Res; 17(17); 5615–25. ©2011 AACR.

[1]  H. Heslop,et al.  High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. , 2011, Blood.

[2]  M. V. van Loenen,et al.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies , 2009, Haematologica.

[3]  T. Blankenstein,et al.  Transgenic mice with a diverse human T cell antigen receptor repertoire , 2010, Nature Medicine.

[4]  A. Amir,et al.  Mixed T cell receptor dimers harbor potentially harmful neoreactivity , 2010, Proceedings of the National Academy of Sciences.

[5]  D. Busch,et al.  Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. , 2009, Blood.

[6]  M. Kester,et al.  Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy , 2009, Haematologica.

[7]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[8]  F. Lund-Johansen,et al.  Dendritic Cells Engineered to Express Defined Allo‐HLA Peptide Complexes Induce Antigen‐specific Cytotoxic T Cells Efficiently Killing Tumour Cells , 2009, Scandinavian journal of immunology.

[9]  S. Ogawa,et al.  HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. , 2009, Blood.

[10]  K. Rezvani,et al.  Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. , 2009, Blood.

[11]  J. Falkenburg,et al.  Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. , 2009, Experimental hematology.

[12]  H. Heslop,et al.  Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. , 2008, Blood.

[13]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[14]  M. Kester,et al.  Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. , 2007, Blood.

[15]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[16]  S. H. van der Burg,et al.  Detection and Functional Analysis of CD8+ T Cells Specific for PRAME: a Target for T-Cell Therapy , 2006, Clinical Cancer Research.

[17]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Bernards,et al.  The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling , 2005, Cell.

[19]  B. Ljung,et al.  The gene expression signatures of melanoma progression , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Mantovani,et al.  Human renal epithelial cells produce the long pentraxin PTX3. , 2005, Kidney international.

[21]  H. Döhner,et al.  Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens , 2005, Cancer Immunology, Immunotherapy.

[22]  R. Willemze,et al.  Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy , 2004, Leukemia.

[23]  G. Ogg,et al.  Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. , 2004, Blood.

[24]  C. Müller,et al.  Simultaneous expression of T-cell activating antigens in renal cell carcinoma: implications for specific immunotherapy. , 2004, The Journal of urology.

[25]  R. Hagedoorn,et al.  Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer , 2004, The Journal of experimental medicine.

[26]  J. Falkenburg,et al.  New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. , 2004, Blood.

[27]  Els Goulmy,et al.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Yudong D. He,et al.  Expression profiling predicts outcome in breast cancer , 2002, Breast Cancer Research.

[29]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[30]  F. Koning,et al.  Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Ferry Ossendorp,et al.  Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis , 2001, The Journal of experimental medicine.

[32]  J. Goldman,et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000, Blood.

[33]  W. M. Smit,et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. , 1999, Blood.

[34]  B. Seliger,et al.  Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? , 1998, Cancer research.

[35]  Millard,et al.  PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells , 1998, British journal of haematology.

[36]  J. Shabanowitz,et al.  The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. , 1998, Science.

[37]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[38]  Y. Sonoda,et al.  Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. , 1997, Blood.

[39]  P. Coulie,et al.  Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. , 1997, Immunity.

[40]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.

[41]  H. V. van Houwelingen,et al.  Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. , 1996, The New England journal of medicine.

[42]  H. Deeg,et al.  Prolonged disease-free survival in dogs with lymphoma after total-body irradiation and autologous marrow transplantation consolidation of combination-chemotherapy-induced remissions. , 1979, Blood.